NSE · NEULANDLAB
Neuland Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,053 Cr with net profit ₹364 Cr — a 17.73% net margin, versus 27.38% the period before.
Shareholding
As of 2026-06-30
- Promoter32.62%
- Public29.79%
- FII21.08%
- DII16.51%
44,340 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.75× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #3 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,01,132 Cr | 267.63 | 11.98 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,101 Cr | 205.73 | 16.39 | 21.54% | 26.6% |
| Neuland Laboratories Ltd.(this company) | ₹24,569 Cr | 115.53 | 13.18 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,587 Cr | 129.62 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,724 Cr | 67.44 | 2.4 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,685 Cr | 109.92 | 4.69 | 12.98% | 11.5% |
| Hikal Limited | ₹2,736 Cr | 189.68 | 2.29 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,250 Cr | 248.57 | 9.2 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹1,994 Cr | 147.88 | 6.06 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,341 Cr | 68.41 | 3.22 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashNeuland Laboratories Ltd. has a market capitalization of Rs 24311 Cr. The company reported annual revenue of Rs 1497.35 Cr with a profit margin of 17.99%. Its book value is Rs 1460.31 and earnings per share (EPS) stands at Rs 281.46. The stock's 52-week high is Rs 20089 and its 52-week low is Rs 11500.
Positives
- +The company has a low debt-to-equity ratio of 0.13.
- +Return on Capital Employed (ROCE) is 23.57%, indicating efficient use of capital.
- +The dividend yield is 18%.
Negatives
- −Revenue growth for the company is negative at -5.2%.
- −The profit margin is 17.99%, which could be impacted by market dynamics.
- −A portion of promoter shares, specifically 2.29%, is pledged.
- −The P/E ratio is high at 114.32.
Financial Performance
Neuland Laboratories Ltd. reported annual revenue of Rs 1497.35 Cr, which reflects a revenue growth of -5.2%. The net profit margin for the company is 17.99%. Over the last four quarters, the company's revenue has fluctuated, with Rs 398.03 Cr in Dec 2024, Rs 328.36 Cr in Mar 2025, Rs 292.75 Cr in Jun 2025, and Rs 514.27 Cr in Sep 2025.
Profitability & Returns
The company's profit margin is 17.99%. Return on equity (ROE) is 19.42% and Return on Capital Employed (ROCE) is 23.57%. The earnings per share (EPS) is Rs 281.46, and the price-to-earnings (PE) ratio stands at 114.32.
Balance Sheet
Neuland Laboratories Ltd. maintains a debt-to-equity ratio of 0.13, indicating a low reliance on debt financing. The book value per share is Rs 1460.31. The company demonstrates a dividend yield of 18%.
Ownership & Pledges
Total institutional holding is 37.5961%, with 44340 shareholders. Davuluri Saharsh Rao, a promoter, has pledged 96,000 shares, representing 49.2% of their individual holding as of March 31, 2026.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.